Wieloletnie doświadczenia z zastosowaniem ranibizumabu w leczeniu postaci wysiękowej AMD – przykłady kliniczne
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2014
Słowa kluczowe:
AMD, leczenie anty-VEGF, ranibizumab
##plugins.themes.bootstrap3.article.main##
Abstrakt
Podejmowane od wielu lat próby leczenia wysiękowej postaci AMD zaowocowały opracowaniem i wprowadzeniem do praktyki klinicznej leków blokujących aktywność VEGF. Spośród obecnie dostępnych leków stosowany od ośmiu lat ranibizumab ma najmocniej udowodnione w badaniach klinicznych skuteczność i bezpieczeństwo. We własnym materiale kilku tysięcy iniekcji zaobserwowaliśmy minimalną liczbę działań niepożądanych, w tym żadnych poważnych niepożądanych działań leku. Przedstawiamy przypadki kliniczne pacjentów z wysiękową postacią AMD leczonych skutecznie w długim okresie za pomocą iniekcji doszklistkowych ranibizumabu. Lek ten obecnie stosujemy z powodzeniem nie tylko w wysiękowym AMD, ale także w czterech innych wskazaniach: BRVO, CRVO, DME i mCNV.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Wykrota H, Trzciąkowski K. Wieloletnie doświadczenia z zastosowaniem ranibizumabu w leczeniu postaci wysiękowej AMD – przykłady kliniczne. Ophthatherapy [Internet]. 30 czerwiec 2014 [cytowane 22 listopad 2024];1(2):76-3. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/674
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997; 115(6): 741-7.
2. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994; 112(4): 480-8.
3. Bressler N. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials – tap report 2. Arch Ophtalmol. 2001; 119(2): 198-207.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin Therapy for Subfoveal Choroidal Neowascularization in Age-Related Macular degeneration. Arch Ophthalmol. 2002; 120: 1307-14.
5. Tatar O., Adam A., Shinoda K. et al.: Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006; 142(1): 95-104.
6. Ferrara N, Gerber H, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003; 99(6): 669-76.
7. Gragoudas E, Adamis A, Cunningham E et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27): 2805-16.
8. Avery R, Pieramici D, Rabena M et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113 (3): 363-72.
9. Rosenfeld P, Brown D, Heier J et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419-31.
10. Larsen M, Schmidt-Erfurth U, Lanzetta P et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology. 2012; 119(5): 992-1000.
11. Holz G, Amoaku W, Donate J et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology. 2011; 118(4): 663-71.
12. Chakravarthy U, Harding S, Rogers C et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 9900(382): 1258-67.
13. Kaiser P, Boyer D, Cruess A et al; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012; 119(5): 1001-10.
14. Busbee B, Ho A, Brown D et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5): 1046-56.
15. Mitchell P, Korobelnik J, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010; 94(1): 2-13.
16. Ying G, Kim B, Maguire M et al; for the CATT Research Group. Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2014 May 29. https://doi.org/10.1001/jamaophthalmol.2014.1019.
17. Fung A, Lalwani G, Rosenfeld P et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-83.
18. Lalwani G, Rosenfeld P, Fung A et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.
19. Jackson T, Dugel P, Bebchuk J et al.; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology. 2013; 120(8): 1597-603.
20. Schmidt-Erfurth U, Kaiser P, Korobelnik J et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014; 121(1): 193-201.
21. Holz F, Bandello F, Gillies M et al; on behalf of the LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Br J Ophthalmol. 2013; 97(9): 1161-7.
22. Lucentis (ranibizumab). Charakterystyka produktu leczniczego. 05.2014.
2. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994; 112(4): 480-8.
3. Bressler N. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials – tap report 2. Arch Ophtalmol. 2001; 119(2): 198-207.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin Therapy for Subfoveal Choroidal Neowascularization in Age-Related Macular degeneration. Arch Ophthalmol. 2002; 120: 1307-14.
5. Tatar O., Adam A., Shinoda K. et al.: Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006; 142(1): 95-104.
6. Ferrara N, Gerber H, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003; 99(6): 669-76.
7. Gragoudas E, Adamis A, Cunningham E et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27): 2805-16.
8. Avery R, Pieramici D, Rabena M et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113 (3): 363-72.
9. Rosenfeld P, Brown D, Heier J et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419-31.
10. Larsen M, Schmidt-Erfurth U, Lanzetta P et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology. 2012; 119(5): 992-1000.
11. Holz G, Amoaku W, Donate J et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology. 2011; 118(4): 663-71.
12. Chakravarthy U, Harding S, Rogers C et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 9900(382): 1258-67.
13. Kaiser P, Boyer D, Cruess A et al; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012; 119(5): 1001-10.
14. Busbee B, Ho A, Brown D et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5): 1046-56.
15. Mitchell P, Korobelnik J, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010; 94(1): 2-13.
16. Ying G, Kim B, Maguire M et al; for the CATT Research Group. Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. 2014 May 29. https://doi.org/10.1001/jamaophthalmol.2014.1019.
17. Fung A, Lalwani G, Rosenfeld P et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-83.
18. Lalwani G, Rosenfeld P, Fung A et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.
19. Jackson T, Dugel P, Bebchuk J et al.; CABERNET Study Group. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology. 2013; 120(8): 1597-603.
20. Schmidt-Erfurth U, Kaiser P, Korobelnik J et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014; 121(1): 193-201.
21. Holz F, Bandello F, Gillies M et al; on behalf of the LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Br J Ophthalmol. 2013; 97(9): 1161-7.
22. Lucentis (ranibizumab). Charakterystyka produktu leczniczego. 05.2014.